When people search for a natural remedy for stress, they often reach for adaptogens — herbs that work directly on the body's cortisol and HPA axis response. Lion's Mane (Hericium erinaceus) is not an adaptogen. It does not lower cortisol directly. It does not switch off your fight-or-flight response in the way Ashwagandha or Rhodiola might.

And yet, some of the most compelling preliminary human data we have on any functional mushroom involves stress and anxiety outcomes — and it all comes back to Lion's Mane.

So how does a mushroom that has no direct relationship with cortisol produce measurable reductions in stress and anxiety in randomised controlled trials? The answer lies in what researchers call the indirect pathway: Lion's Mane's proposed ability to support nerve growth factor (NGF) synthesis and neuroplasticity in the brain — and through that mechanism, to gradually reshape how the brain processes and responds to stress.

This article examines what the research actually shows, where the evidence is strong, where it is preliminary, and who this approach is genuinely suited for. For a broader overview of everything this mushroom does, see our complete Lion's Mane guide.

The NGF Pathway: A Different Kind of Stress Support

Nerve growth factor (NGF) is a protein that plays a central role in the maintenance and repair of neurons, particularly in the hippocampus — the brain region most closely associated with memory, learning, and emotional regulation. Chronic stress is well established as a driver of hippocampal shrinkage. When the hippocampus is under-supported, stress reactivity increases, anxiety becomes more pronounced, and cognitive fatigue deepens.

Lion's Mane contains two groups of bioactive compounds — hericenones (found in the fruiting body) and erinacines (found in the mycelium) — that have been shown in laboratory and animal studies to stimulate NGF synthesis. The proposed mechanism is that by supporting NGF levels, Lion's Mane may help maintain or restore hippocampal neuroplasticity, gradually reducing the neural substrate of stress sensitivity over time.

This is a fundamentally different mechanism from cortisol suppression. It is slower, more structural, and — if the evidence holds in larger human trials — potentially more durable.

It is also important to be precise: the hericenones and erinacines cannot cross the blood-brain barrier in their extracted form. Erinacine A, which has shown the most potent NGF-stimulating activity in animal models, requires mycelium-sourced extract. This matters when comparing products.

Human Evidence: What the Randomised Controlled Trials Show

Study 1: Stress and Anxiety in Healthy Young Adults (2023)

The most directly relevant human trial was published in 2023 (PMID: 38004235). This was a double-blind, placebo-controlled randomised controlled trial involving n = 41 healthy young adults. Participants received 1.8 g/day of Lion's Mane fruiting body extract (HEP — Hericium erinaceus powder) for 28 days.

The results showed a statistically significant reduction in self-reported stress and anxiety as measured by the DASS-21 (Depression Anxiety Stress Scales), along with improved mood ratings. These are meaningful findings from a well-designed trial.

However — and this is important to report honestly — the same study found no significant effect on processing speed. Cognitive speed tasks showed no improvement over the 28-day period. This suggests Lion's Mane's impact on stress-related wellbeing may precede, or operate independently of, cognitive performance improvements. It is a finding that deserves acknowledgement rather than dismissal.

The sample size (n = 41) is small. This is preliminary evidence, not a settled clinical finding. More research with larger cohorts and longer durations is needed before firm conclusions can be drawn.

Study 2: Anxiety and Irritability in Perimenopausal Women (2010 — see 2019)

A second human randomised controlled trial (PMID: 31413233, published 2019) examined Lion's Mane in n = 30 women experiencing menopausal transition, over 4 weeks at 2 g/day. The study was not specifically focused on stress — it examined quality of life, concentration, and mood. It found reduced self-reported anxiety and irritability in the Lion's Mane group compared to placebo.

Again, this is a small pilot study. It cannot be extrapolated broadly, and the menopausal context introduces hormonal variables that may influence outcomes. Limitation: the participant group limits generalisation to the broader population.

Study 3: Cognitive Support in Older Adults with Mild Cognitive Impairment (2009)

An earlier RCT (PMID: 18844328) examined Lion's Mane in n = 30 older adults with mild cognitive impairment. Participants received 3 g/day over 16 weeks and showed significant improvement on the MMSE (Mini-Mental State Examination). This study was not designed to measure stress or anxiety outcomes directly, but it provides evidence that the neurological mechanisms proposed — sustained over longer durations at higher doses — do produce measurable cognitive support in human populations.

Preclinical Evidence: Animal Studies on the NGF-Stress Link

Beyond the human RCTs, there is a body of animal and in vitro research that helps build the mechanistic picture — though it is important to distinguish this from human clinical evidence.

A 2010 mouse study (PMID: 20834180) demonstrated that erinacine A — an NGF-stimulating compound found in Lion's Mane mycelium — reduced depressive-like behaviour in mice subjected to the forced swim test, a standard model of despair-like states in rodents. The researchers observed changes consistent with NGF pathway activation.

A 2021 review (PMID: 34865649) discussed the proposed NGF pathway and its implications for neuroplasticity, covering both in vitro cell studies and animal model data. The authors noted that the preclinical mechanistic evidence is reasonably consistent, but that human RCT data remain limited — a characterisation that is still accurate today.

Animal studies suggest that erinacine A and hericenones can stimulate NGF activity in neural tissue. The translation of these findings to human outcomes, however, is not yet proven at scale. Preclinical results should be understood as hypothesis-generating, not clinically conclusive.

Who Is Lion's Mane for Stress Actually Suited To?

For a direct comparison of the two approaches, see our article on Lion's Mane vs Ashwagandha. The two are not mutually exclusive — they work via different mechanisms and can complement each other.

What the RCT Data Tells Us About Dose and Duration

Drawing directly from the human trial data, the dosages used in studies reporting stress and anxiety outcomes range from 1.8 g/day (the 2023 RCT, PMID: 38004235, 28 days, n = 41) to 2 g/day (the 2019 menopause RCT, PMID: 31413233, 4 weeks, n = 30) to 3 g/day (the 2009 cognitive impairment RCT, PMID: 18844328, 16 weeks, n = 30).

A few practical observations from this data:

• No study used less than 1.8 g/day and observed meaningful outcomes
• The minimum study duration across relevant trials was 4 weeks — consistent with the proposed neuroplasticity mechanism, which is inherently a slower process
• The cognitive impairment study, which used the highest dose (3 g/day) over the longest period (16 weeks), produced the strongest cognitive outcomes — though this was a different population and different primary endpoint
• The 2023 RCT found no processing speed improvement over 28 days — suggesting that stress and mood outcomes may appear before cognitive speed benefits

For practical guidance on how to take Lion's Mane, when to take it, and what to pair it with, see our dosage guide.

A 2024 systematic review (PMID: 40626304) examined mood and cognitive outcomes across multiple Lion's Mane trials and broadly concluded that the evidence is promising but that larger, longer trials are needed. This is an accurate characterisation of where the field stands — early but credible, not not proven.

The Stress-Anxiety Overlap: What You Can and Cannot Infer

It is worth being precise about what the research measures and what it does not. The DASS-21 instrument used in the 2023 RCT captures self-reported subjective experience of stress and anxiety. It does not measure cortisol, HPA axis activity, or sympathetic nervous system parameters.

This means the data tells us that participants felt less stressed and anxious — which is a meaningful outcome — but does not confirm the proposed NGF mechanism as the cause. It is plausible, consistent with preclinical data, and the most likely explanation. But the mechanism remains theoretical in the context of these human studies.

For a more focused examination of the anxiety angle specifically, including what is known about the hippocampal neuroplasticity pathway, see our article on Lion's Mane for anxiety.

The honest summary: two small RCTs found meaningful reductions in stress and anxiety using Lion's Mane supplementation. The proposed mechanism — NGF-mediated neuroplasticity — is supported by preclinical data but not yet proven at scale in humans. This is early-stage evidence. It is not sufficient to make definitive clinical claims, but it is sufficient to warrant serious attention.

Frequently Asked Questions

This article is for educational purposes only and is not intended to diagnose, treat, cure or prevent any disease. The information presented here is based on published research and is intended for general educational purposes only. Individual results may vary. Always consult a qualified healthcare professional before starting any new supplement, particularly if you have a diagnosed medical condition or are taking medication.